NHS-PEG1-SS-PEG1-NHS is a reversible linker used for interacting biomolecules with active small molecules and is effective for linking protein liposomes or nanoparticles (NHS-PEG1-SS-PEG1-NHS).
Thalidomide-O-amido-C3-PEG3-C1-NH2 is a synthesized conjugate compound serving as an E3 ligase ligand-linker, featuring a cereblon ligand based on Thalidomide and a 3-unit PEG linker, specifically designed for use in PROTAC technology.
NH2-PEG2-CH2-Boc is a PEG-based linker for PROTACs, enabling the conjugation of two essential ligands for PROTAC molecule formation. This linker facilitates selective protein degradation by leveraging the ubiquitin-proteasome system within cells.
Pomalidomide-amino-PEG4-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, incorporates the cereblon ligand derived from Pomalidomide, along with a linker commonly employed in PROTAC technology.
Thalidomide-Piperazine-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that combines a Thalidomide-based cereblon ligand with a linker commonly used in [PROTAC] technology, functioning as an E3 ligase recruiter.
DBCO-PEG4-MMAF is an antibody-drug conjugate (ADC) component that exhibits potent antitumor activity. It combines the tubulin polymerization inhibitor MMAF with a cleavable linker, DBCO-PEG4, to target cancer cells effectively.
Pomalidomide-PEG3-CO2H (Thalidomide-NH-PEG3-propionic acid) is a synthesized E3 ligase ligand-linker conjugate. Pomalidomide-PEG3-CO2H incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.
